Advances in immunotherapy for melanoma management

References

• Vennepureddy A, Thumallapally N, Nehru VM, Atallah J, Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res 2016; 8:63
   PubMedGoogle Scholar
• Miller AJ, Mihm Jr MC. Melanoma. N Engl J Med 2006; 355:51-65
   PubMed Web of Science ®Google Scholar
• Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: Different regional disease and poorer prognosis. J Cancer 2011; 2:538-43; PMID:22084644
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget 2014; 5:1701-52; PMID:24743024
   PubMed Web of Science ®Google Scholar
• La‐Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: New insights and current place in cancer therapy. Pharmacotherapy 2015; 35:963-76
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class I-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005; 174:7853-8; PMID:15944290
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
   PubMed Web of Science ®Google Scholar
• Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20:3446-57; PMID:24812408; http://dx.doi.org/10.1158/1078-0432.CCR-13-2797
   PubMed Web of Science ®Google Scholar
• Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4:535-43
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443
   PubMed Web of Science ®Google Scholar
• Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015; 125:3377-83; PMID:26325034; http://dx.doi.org/10.1172/JCI80012
   PubMed Web of Science ®Google Scholar
• Harvey RD. Immunologic and clinical effects of targeting PD‐1 in lung cancer. Clinical Pharmacology & Therapeutics 2014; 96:214-23
   PubMed Web of Science ®Google Scholar
• Delyon J, Maio M, Lebbe C. The ipilimumab lesson in melanoma: Achieving long-term survival. Semin Oncol 2015; 42:387-401; PMID:25965357; http://dx.doi.org/10.1053/j.seminoncol.2015.02.005
   PubMed Web of Science ®Google Scholar
• Camacho LH. CTLA-4 blockade with ipilimumab: Biology, safety, efficacy, and future considerations. Cancer Med 2015; 4:661-72; PMID:25619164; http://dx.doi.org/10.1002/cam4.371
   PubMed Web of Science ®Google Scholar
• Delyon J, Maio M, Lebbe C. The ipilimumab lesson in melanoma: Achieving long-term survival. Semin Oncol 2015; 42:387-401; PMID:25965357
   PubMed Web of Science ®Google Scholar
• Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1:220-8; PMID:11905831; http://dx.doi.org/10.1038/35105024
   PubMed Web of Science ®Google Scholar
• Michielin O, Hoeller C. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev 2015; 41:660-70; PMID:26096079; http://dx.doi.org/10.1016/j.ctrv.2015.05.012
   PubMed Web of Science ®Google Scholar
• Trinh VA, Hagen B. Ipilimumab for advanced melanoma: A pharmacologic perspective. J Oncol Pharm Pract 2013; 19:195-201; PMID:23047236; http://dx.doi.org/10.1177/1078155212459100
   PubMedGoogle Scholar
• Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F. The european medicines agency review of ipilimumab (yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the committee for medicinal products for human use. Eur J Cancer 2012; 48:237-42
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-42; PMID:24838938; http://dx.doi.org/10.1158/2326-6066.CIR-14-0053
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, et al. Phase I study of ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-hodgkin lymphoma. Clin Cancer Res 2009; 15:6446-53; PMID:19808874; http://dx.doi.org/10.1158/1078-0432.CCR-09-1339
   PubMed Web of Science ®Google Scholar
• Ribas A. Anti-CTLA4 antibody clinical trials in melanoma. Update Cancer Ther 2007; 2:133-9; PMID:19543441; http://dx.doi.org/10.1016/j.uct.2007.09.001
   PubMedGoogle Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol 2015; 42:429-35; PMID:25965361
   PubMed Web of Science ®Google Scholar
• Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-82; PMID:23400564; http://dx.doi.org/10.1002/cncr.27969
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23
   PubMed Web of Science ®Google Scholar
• Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29:455-63; PMID:16799341; http://dx.doi.org/10.1097/01.cji.0000208259.73167.58
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: A review of clinical experience and future prospects. Clin Cancer Res 2014; 20:6258-68; PMID:25341541; http://dx.doi.org/10.1158/1078-0432.CCR-14-1457
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570; http://dx.doi.org/10.1245/ASO.2005.03.536
   PubMed Web of Science ®Google Scholar
• Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23:263-72; PMID:11444391
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9; PMID:20551059; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-72; PMID:8671665
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95; PMID:1396582
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8:793-800
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099
   PubMed Web of Science ®Google Scholar
• Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015; 3:1-13
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30
   PubMed Web of Science ®Google Scholar
• Tarhini AA. Immunotherapy of melanoma. Curr Mol Pharmacol 2015; PMID:26177647.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54
   PubMed Web of Science ®Google Scholar
• Cha E, Wallin J, Kowanetz M. PD-L1 inhibition with MPDL3280A for solid tumors. 2015; 42:484-7
   Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu W, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med 2013; 369:134-44
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26):2521-32; http://dx.doi.org/10.1056/NEJMoa1503093; Epub 2015 Apr 19
   Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7
   PubMed Web of Science ®Google Scholar
• Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology 2015; 16:375-84
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R, Reed K. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34
   PubMed Web of Science ®Google Scholar
• Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014; 111:11774-9; PMID:25071169; http://dx.doi.org/10.1073/pnas.1410626111
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014; 2:643-54; PMID:24903021; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nature reviews Drug discovery 2015; 14:561-84
   PubMed Web of Science ®Google Scholar
• Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 1994; 180:757-62; PMID:7913952
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162:1818-26; PMID:9973447
   PubMed Web of Science ®Google Scholar
• Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161:6510-7; PMID:9862675
   PubMed Web of Science ®Google Scholar
• Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106
   PubMed Web of Science ®Google Scholar
• Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, Imamura S, Uchiyama T. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996; 183:2185-95; PMID:8642328
   PubMed Web of Science ®Google Scholar
• Alderson MR, Smith CA, Tough TW, Davis‐Smith T, Armitage RJ, Falk B, Roux E, Baker E, Sutherland GR, Din WS. Moslecular and biological characterization of human 4‐1BB and its ligands. Eur J Immunol 1994; 24:2219-27
   PubMed Web of Science ®Google Scholar
• Cheuk AT, Mufti GJ, Guinn B. Role of 4-1BB: 4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004; 11:215-26
   PubMed Web of Science ®Google Scholar
• Li S, Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clinical pharmacology: advances and applications 2013; 5:47
   PubMedGoogle Scholar
• Orloff M, Valsecchi ME, Sato T. Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs 2015; 24:993-7
   PubMed Web of Science ®Google Scholar
• Sznol M, Hodi F, Margolin K, McDermott D, Ernstoff M, Kirkwood J, Wojtaszek C, Feltquate D, Logan T. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). 2008; 26:3007
   Google Scholar
• Sanmamed MF, Rodriguez I, Schalper KA, Onate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Perez-Gracia JL, Martin-Algarra S, et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rgammanull immunodeficient mice. Cancer Res 2015; 75:3466-78; PMID:26113085; http://dx.doi.org/10.1158/0008-5472.CAN-14-3510
   PubMed Web of Science ®Google Scholar
• Makkouk A, Chester C, Kohrt HE. Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer 2016; 54:112-9
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Lee DJ, Faries MB. Melanoma vaccines: Mixed past, promising future. Surg Clin North Am 2014; 94:1017-30
   PubMed Web of Science ®Google Scholar
• Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 2002; 20:4169-80; PMID:12377960
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. 2003; 13:401-7
   Google Scholar
• Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Melanoma vaccines: Developments over the past 10 years. 2011
   Google Scholar
• Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor >1.5 mm in patients with stage II melanoma: Results of the EORTC 18961 randomized phase III trial. J Clin Oncol 2013; 31:3831-7; PMID:24019551; http://dx.doi.org/10.1200/JCO.2012.47.9303
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA. The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 1998; 21:237-46
   PubMed Web of Science ®Google Scholar
• Zarour HM, Kirkwood JM. Melanoma vaccines: Early progress and future promises. 2003; 22:68-75
   Google Scholar
• Nesrua FO, Atuaolcl S, GILLIE M, SUNZ Y, Gimasr S. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Peptides 1:A2
   Google Scholar
• Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HMH, Gerritsen MP, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011; 60:249-60
   PubMed Web of Science ®Google Scholar
• Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunol Immunother 2016; 65:383-92
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. 2013; 31:LBA9008
   Google Scholar
• Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. 2014; 32:9029
   Google Scholar
• Jabulowsky RA, Loquai C, Diken M, Kranz LM, Haas H, Attig S, Britten CM, Buck J, Derhovanessian E, Diekmann J. Abstract B041: A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma. Cancer Immunol Res 2016; 4:B041
   PubMed Web of Science ®Google Scholar
• Butterfield LH. Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 2016; 1-8
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
   PubMed Web of Science ®Google Scholar
• Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308
   PubMed Web of Science ®Google Scholar
• Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 24:5060-9; PMID:17075125
   PubMed Web of Science ®Google Scholar
• Khammari A, Nguyen J, Saint-Jean M, Knol A, Pandolfino M, Quereux G, Brocard A, Peuvrel L, Saiagh S, Bataille V. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother 2015; 64:805-15
   PubMed Web of Science ®Google Scholar